GlaxoSmithKline Buys Okairos for Approx. $325 Mln
GlaxoSmithKline, the global healthcare company, said on Wednesday that it has acquired Okairos AG, a Swiss-based developer of vaccine platform technologies for €250 million (approximately $325 million) in cash. The transaction will also include some early stage assets. Prior to the acquisition, Okairos was backed by the following life science VC firms: BioMedInvest, the Boehringer Ingelheim Venture Fund, LSP, Novartis Venture Funds and Versant Ventures.
29 May 2013•3 mins read
